2020
14 October, 2020
FluoGuide A/S presents at BioStock Live
Together with four other Life Science companies, FluoGuide will present at BioStock Live from their studio at Medicon Village in Lund...
21 September, 2020
FluoGuide appoints Henrik Moltke as Chief Financial Officer
FluoGuide wants to strengthen its partnering, financing and other commercial activities to take full advantages of the upcoming results...
FluoGuide appreciates that the Danish Medicines Agency wants to conduct an audit of the clinical trial site at Rigshospitalet to provide...
“The latest development in share price sets the expectations high which we do our outmost to deliver on. I wish to thank our...
FluoGuide’s strategic development plan centers on advancing its lead product, FG001, for targeted glioblastoma surgery, and on...
The preclinical studies needed to support human clinical trials for FG001 have now been completed and reported. The clean outcome of...
30 June, 2020
Dorthe Grønnegaard Mejer joins FluoGuide A/S as Vice President of Clinical Development
The clinical development of FG001 for use to guide surgery of aggressive brain cancer (glioblastoma) can be very short until approval...
8 June, 2020
FluoGuide A/S selected as a top innovator and awarded €2.5 million by the European Innovation Council
FluoGuide is preparing a proof-of-concept clinical study (phase I/IIa) to demonstrate the effect of FG001 in patients with glioblastoma...
”The entire FluoGuide team is working hard to capture the enormous potential of the Company to help patients and benefit shareholders...